Company intelligence / Profile preview

ApolloBio

China

Ownership: Private
Development stage: Other

Overview

ApolloBio's lead program, bizalimogene ralaplasmid (VGX-3100), is in Phase 3 development for squamous intraepithelial lesions of the cervix associated with HPV16/18, with promising efficacy and safety noted in earlier studies. Additional preclinical programs target COVID-19 (ABC-5100, a DNA vaccine) and various solid tumors (ABC-177).

Therapeutic areas: OncologyInfectious DiseasesWomen's Health
Modalities: DNA vaccineSmall moleculeAntibodyCAR-T cell therapyVaccine
Industry: Biotech

Drug pipeline

1 asset

ABC-5100

Preclinical

Partnerships

Inovio Pharmaceuticals

Beyond the preview

Go deeper on ApolloBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ApolloBio.

Explore the full profile